In a recent study, Fraietta and colleagues identified chimeric antigen receptor (CAR) T cell biomarkers that may predict the success or failure of CAR therapy in patients with refractory chronic lymphoblastic leukemia (CLL). These findings open new prospects for improving T cell product manufacturing and the management of patients with CLL undergoing T cell-based therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.molmed.2018.06.007 | DOI Listing |
Publication Analysis
Top Keywords
chimeric antigen
8
antigen receptor
8
chronic lymphoblastic
8
lymphoblastic leukemia
8
insights chimeric
4
receptor therapy
4
therapy chronic
4
leukemia study
4
study fraietta
4
fraietta colleagues
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!